The Cancer Test That Wall Street Is Betting On
The Rise of Liquid Biopsy Technology Natera, a biotechnology firm specializing in genetic testing, has established a dominant market position in the field of molecular residual disease (MRD) testing, a breakthrough approach that utilizes blood samples to detect the recurrence of cancer in survivors. As of late 2024, the company’s Signatera test has become the…